Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L P Rivory

Showing results (1-10 of 49) with videos related to

Pageof 5
Sort By:
Clinical and Experimental Pharmacology & Physiology|October 1, 1996
Irinotecan (CPT-11): a brief overviewL P Rivory
Annals of the New York Academy of Sciences|February 24, 2001
Metabolism of CPT-11. Impact on activityL P Rivory
Journal of Chromatography. B, Biomedical Applications|November 4, 1994
Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasmaL P Rivory, J Robert
Pharmacology & Therapeutics|January 1, 1995
Molecular, cellular, and clinical aspects of the pharmacology of 20(S)camptothecin and its derivativesL P Rivory, J Robert
Bulletin Du Cancer|April 1, 1995
[Pharmacology of camptothecin and its derivatives]L P Rivory, J Robert
Cancer Chemotherapy and Pharmacology|January 1, 1995
Identification and kinetics of a beta-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecanL P Rivory, J Robert
Clinical Pharmacokinetics|March 27, 1999
Clinical pharmacokinetics of docetaxelS J Clarke, L P Rivory
Clinical Pharmacology and Therapeutics|October 24, 2001
Erythromycin breath testL P Rivory, P B Watkins
Molecular Pharmacology|November 26, 1999
The mechanism for the inhibition of acetylcholinesterases by irinotecan (CPT-11)H M Dodds, L P Rivory
British Journal of Pharmacology|September 21, 2001
Comment on a published paper. The adverse cholinergic effects of the chemotherapeutic agent irinotecan (CPT-11) were unlikely to be mediated by the inhibition of acetylcholinesterase (AChE)H M Dodds, L P Rivory
Pageof 5

Showing results (1-10 of 49) with videos related to

Sort By:
Pageof 5
Clinical and Experimental Pharmacology & Physiology|October 1, 1996
Irinotecan (CPT-11): a brief overviewL P Rivory
Annals of the New York Academy of Sciences|February 24, 2001
Metabolism of CPT-11. Impact on activityL P Rivory
Journal of Chromatography. B, Biomedical Applications|November 4, 1994
Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasmaL P Rivory, J Robert
Pharmacology & Therapeutics|January 1, 1995
Molecular, cellular, and clinical aspects of the pharmacology of 20(S)camptothecin and its derivativesL P Rivory, J Robert
Bulletin Du Cancer|April 1, 1995
[Pharmacology of camptothecin and its derivatives]L P Rivory, J Robert
Cancer Chemotherapy and Pharmacology|January 1, 1995
Identification and kinetics of a beta-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecanL P Rivory, J Robert
Clinical Pharmacokinetics|March 27, 1999
Clinical pharmacokinetics of docetaxelS J Clarke, L P Rivory
Clinical Pharmacology and Therapeutics|October 24, 2001
Erythromycin breath testL P Rivory, P B Watkins
Molecular Pharmacology|November 26, 1999
The mechanism for the inhibition of acetylcholinesterases by irinotecan (CPT-11)H M Dodds, L P Rivory
British Journal of Pharmacology|September 21, 2001
Comment on a published paper. The adverse cholinergic effects of the chemotherapeutic agent irinotecan (CPT-11) were unlikely to be mediated by the inhibition of acetylcholinesterase (AChE)H M Dodds, L P Rivory
Pageof 5